{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T21:51:25Z","timestamp":1782769885556,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Angiotensin II receptor blockers (ARBs), including olmesartan and candesartan, are widely used antihypertensive agents. Many clinical studies have demonstrated that ARBs have organ-protecting effects, e.g., cardioprotection, vasculoprotection and renoprotection. However, the effect of prolonged olmesartan monotherapy on lipid metabolism in patients with hypertension is less well studied. We performed a retrospective observational study to compare the effects of olmesartan with those of candesartan, focusing on lipid metabolism and renal function.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We used data from the Clinical Data Warehouse of Nihon University School of Medicine obtained between Nov 1, 2004 and Feb 28, 2011, to identify cohorts of new olmesartan users (n = 168) and candesartan users (n = 266). We used propensity-score weighting to adjust for differences in all covariates (age, sex, comorbid diseases, previous drugs) between olmesartan and candesartan users, and compared serum chemical data including serum triglyceride (TG), LDL-cholesterol (LDL-C), total cholesterol (TC), potassium, creatinine and urea nitrogen. The mean exposure of olmesartan and candesartan users was 126.1 and 122.8 days, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>After adjustment, there were no statistically significant differences in all covariates between olmesartan and candesartan users. The mean age was 60.7 and 61.0 years, and 33.4% and 33.7% of olmesartan and candesartan users were women, respectively. There were no statistically significant differences in mean values for all laboratory tests between baseline and during the exposure period in both olmesartan and candesartan users. In olmesartan users, the reduction of serum TG level was significant in comparison with that in candesartan users. Other parameters of lipid profile and renal function showed no statistically significant difference in the change from baseline to during the exposure period between olmesartan and candesartan users.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In this study, we observed a more beneficial effect on lipid metabolism, a reduction of serum TG, with olmesartan monotherapy than with candesartan monotherapy. However, there were no clinically significant changes in the levels of all test parameters between baseline and during the exposure period with both drugs. These results suggest that the influence of olmesartan or candesartan monotherapy on lipid metabolism and renal function is small, and that they can be safely used in patients with hypertension.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1475-2840-10-74","type":"journal-article","created":{"date-parts":[[2011,8,10]],"date-time":"2011-08-10T06:18:53Z","timestamp":1312957133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study"],"prefix":"10.1186","volume":"10","author":[{"given":"Yayoi","family":"Nishida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Soma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,10]]},"reference":[{"key":"382_CR1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1291\/hypres.28.593","volume":"28","author":"S Takai","year":"2005","unstructured":"Takai S, Kirimura K, Jin D, Muramatsu M, Yoshikawa K, Mino Y, Miyazaki M: Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res. 2005, 28: 593-600. 10.1291\/hypres.28.593.","journal-title":"Hypertens Res"},{"key":"382_CR2","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","volume":"362","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, CHARM Investigators and Committees: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003, 362: 759-766. 10.1016\/S0140-6736(03)14282-1.","journal-title":"Lancet"},{"key":"382_CR3","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"HH Parving","year":"2001","unstructured":"Parving HH, Lehnert H, Br\u00f6chner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001, 345: 870-878. 10.1056\/NEJMoa011489.","journal-title":"N Engl J Med"},{"key":"382_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1475-2840-9-60","volume":"9","author":"E Ritz","year":"2010","unstructured":"Ritz E, Schmieder RE, Pollock CA: Renal protection in diabetes: lessons from ONTARGET. Cardiovasc Diabetol. 2010, 9: 60-10.1186\/1475-2840-9-60.","journal-title":"Cardiovasc Diabetol"},{"key":"382_CR5","first-page":"22","volume":"36","author":"MA Munger","year":"2011","unstructured":"Munger MA: Use of angiotensin receptor blockers in cardiovascular protection: current evidence and future directions. P T. 2011, 36: 22-40.","journal-title":"P T"},{"key":"382_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-4682-3-1","volume":"3","author":"TG Marshall","year":"2006","unstructured":"Marshall TG, Lee RE, Marshall FE: Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model. 2006, 3: 1-10.1186\/1742-4682-3-1.","journal-title":"Theor Biol Med Model"},{"key":"382_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1475-2840-6-26","volume":"6","author":"N Kitamura","year":"2007","unstructured":"Kitamura N, Takahashi Y, Yamadate S, Asai S: Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records. Cardiovasc Diabetol. 2007, 6: 26-10.1186\/1475-2840-6-26.","journal-title":"Cardiovasc Diabetol"},{"key":"382_CR8","first-page":"377","volume":"5","author":"M Devabhaktuni","year":"2009","unstructured":"Devabhaktuni M, Bangalore S: Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. Vasc Health Risk Manag. 2009, 5: 377-387.","journal-title":"Vasc Health Risk Manag"},{"key":"382_CR9","first-page":"21","volume":"47","author":"SM Kyvelou","year":"2006","unstructured":"Kyvelou SM, Vyssoulis GP, Karpanou EA, Adamopoulos DN, Zervoudaki AI, Pietri PG, Stefanadis CI: Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. Hellenic J Cardiol. 2006, 47: 21-28.","journal-title":"Hellenic J Cardiol"},{"key":"382_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1475-2840-9-38","volume":"9","author":"Y Nishida","year":"2010","unstructured":"Nishida Y, Takahashi Y, Nakayama T, Soma M, Kitamura N, Asai S: Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records. Cardiovasc Diabetol. 2010, 9: 38-10.1186\/1475-2840-9-38.","journal-title":"Cardiovasc Diabetol"},{"key":"382_CR11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJMoa1007994","volume":"364","author":"H Haller","year":"2011","unstructured":"Haller H, Ito S, Izzo JL, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G: ROADMAP Trial Investigators: Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011, 364: 907-917. 10.1056\/NEJMoa1007994.","journal-title":"N Engl J Med"},{"key":"382_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/1753944707085982","volume":"1","author":"KO Stumpe","year":"2007","unstructured":"Stumpe KO, Agabiti-Rosei E, Zielinski T, Schremmer D, Scholze J, Laeis P, Schwandt P, Ludwig M, MORE study investigators: Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis. 2007, 1: 97-106. 10.1177\/1753944707085982.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"382_CR13","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1161\/01.CIR.0000140265.21608.8E","volume":"110","author":"D Fliser","year":"2004","unstructured":"Fliser D, Buchholz K, Haller H, EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators: Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004, 110: 1103-1107. 10.1161\/01.CIR.0000140265.21608.8E.","journal-title":"Circulation"},{"key":"382_CR14","doi-asserted-by":"publisher","first-page":"S206","DOI":"10.1681\/ASN.2006080916","volume":"17","author":"SG de Vinuesa","year":"2006","unstructured":"de Vinuesa SG, Goicoechea M, Kanter J, Puerta M, Cachofeiro V, Lahera V, Gomez-Campdera F, Luno J: Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: Effects of angiotensin II blockade. J Am Soc Nephrol. 2006, 17: S206-S212. 10.1681\/ASN.2006080916.","journal-title":"J Am Soc Nephrol"},{"key":"382_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1291\/hypres.31.43","volume":"31","author":"R Fogari","year":"2008","unstructured":"Fogari R, Derosa G, Zoppi A, Rinaldi A, Preti P, Lazzari P, Mugellini A: Effects of manidipine\/delapril versus olmesartan\/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus. Hypertens Res. 2008, 31: 43-50. 10.1291\/hypres.31.43.","journal-title":"Hypertens Res"},{"key":"382_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1475-2840-10-45","volume":"10","author":"Y Takahashi","year":"2011","unstructured":"Takahashi Y, Nishida Y, Nakayama T, Asai S: Adverse effect profile of trichlormethiazide: a retrospective observational study. Cardiovasc Diabetol. 2011, 10: 45-10.1186\/1475-2840-10-45.","journal-title":"Cardiovasc Diabetol"},{"key":"382_CR17","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","volume":"17","author":"R D'Agostino","year":"1998","unstructured":"D'Agostino R: Tutorial on biostatistics: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998, 17: 2265-2281. 10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B.","journal-title":"Stat Med"},{"key":"382_CR18","volume-title":"SAS Global forum","author":"S Leslie","year":"2007","unstructured":"Leslie S, Thiebaud P: Using propensity score to adjust for treatment selection bias. SAS Global forum. 2007, 184-2007, [http:\/\/www2.sas.com\/proceedings\/forum2007\/184-2007.pdf] paper"},{"key":"382_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika. 1983, 70: 41-55. 10.1093\/biomet\/70.1.41.","journal-title":"Biometrika"},{"key":"382_CR20","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hern\u00e1n MA, Brumback B: Marginal structural models and causal inference in epidemiology. Epidemiology. 2000, 11: 550-560. 10.1097\/00001648-200009000-00011.","journal-title":"Epidemiology"},{"key":"382_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0021-9150(94)05514-J","volume":"115","author":"S Keidar","year":"1995","unstructured":"Keidar S, Kaplan M, Hoffman A, Aviram M: Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis. 1995, 115: 201-215. 10.1016\/0021-9150(94)05514-J.","journal-title":"Atherosclerosis"},{"key":"382_CR22","first-page":"H2701","volume":"272","author":"G Nickenig","year":"1997","unstructured":"Nickenig G, Jung O, Strehlow K, Zolk O, Linz W, Sch\u00f6lkens BA, B\u00f6hm M: Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am J Physiol. 1997, 272: H2701-H2707.","journal-title":"Am J Physiol"},{"key":"382_CR23","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1161\/01.CIR.100.21.2131","volume":"100","author":"G Nickenig","year":"1999","unstructured":"Nickenig G, B\u00e4umer AT, Temur Y, Kebben D, Jockenh\u00f6vel F, B\u00f6hm M: Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 1999, 100: 2131-2134.","journal-title":"Circulation"},{"key":"382_CR24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1161\/01.HYP.0000078490.59735.6E","volume":"42","author":"M Furuhashi","year":"2003","unstructured":"Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension. 2003, 42: 76-81. 10.1161\/01.HYP.0000078490.59735.6E.","journal-title":"Hypertension"},{"key":"382_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijcard.2008.11.017","volume":"140","author":"KK Koh","year":"2010","unstructured":"Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Koh Y, Shin EK: Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol. 2010, 140: 73-81. 10.1016\/j.ijcard.2008.11.017.","journal-title":"Int J Cardiol"},{"key":"382_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1080\/080370598437385","volume":"7","author":"P Trenkwalder","year":"1998","unstructured":"Trenkwalder P, Dahl K, Lehtovirta M, Mulder H: Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes. Blood Press. 1998, 7: 170-175. 10.1080\/080370598437385.","journal-title":"Blood Press"},{"key":"382_CR27","first-page":"1006","volume":"25","author":"G Derosa","year":"2003","unstructured":"Derosa G, Cicero AF, Ciccarelli L, Fogari R: A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clin Ther. 2003, 25: 1006-1021.","journal-title":"Clin Ther"},{"key":"382_CR28","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001, 345: 861-869. 10.1056\/NEJMoa011161.","journal-title":"N Engl J Med"},{"key":"382_CR29","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001, 345: 851-860. 10.1056\/NEJMoa011303.","journal-title":"N Engl J Med"},{"key":"382_CR30","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.jacc.2007.07.067","volume":"50","author":"AS Desai","year":"2007","unstructured":"Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, Dunlap ME, Solomon SD, Hainer JW, Olofsson B, Michelson EL, Pfeffer MA, CHARM Program Investigators: Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol. 2007, 50: 1959-1966. 10.1016\/j.jacc.2007.07.067.","journal-title":"J Am Coll Cardiol"},{"key":"382_CR31","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","volume":"110","author":"JB Young","year":"2004","unstructured":"Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K, Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees: Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004, 110: 2618-2626. 10.1161\/01.CIR.0000146819.43235.A9.","journal-title":"Circulation"},{"key":"382_CR32","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/ajh.2009.138","volume":"22","author":"AS Bomback","year":"2009","unstructured":"Bomback AS, Toto R: Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination. Am J Hypertens. 2009, 22: 1032-1040. 10.1038\/ajh.2009.138.","journal-title":"Am J Hypertens"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1475-2840-10-74.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T15:33:56Z","timestamp":1630510436000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/1475-2840-10-74"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,10]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["382"],"URL":"https:\/\/doi.org\/10.1186\/1475-2840-10-74","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,10]]},"assertion":[{"value":"25 May 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"74"}}